NIKE's sport-focused Win Now reset shows promise, but weak earnings and high valuation cast doubts on near-term upside.
I recommend a hold rating based on falling revenue and headwinds despite a turnaround signaled. Nike has a moat over its competitors, which justifies its high P/E, but the moat is fading and now suggests overvaluation. Next quarter's earnings for Nike are vital to show whether the turnaround will come to fruition.
NKE's global reach faces near-term strain from weak demand and cost pressures, but long-term strategy fuels recovery hopes.
Nike (NKE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
NKE beats on earnings but slumps on revenues as it doubles down on innovation to revive growth and brand strength.
NKE eyes a comeback as it sharpens execution with sport-led innovation, while LULU drives growth via global reach and product expansion.
NKE faces soft demand for classic footwear, offset by growth in performance lines and sportswear innovation.
Zacks.com users have recently been watching Nike (NKE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
After a challenging couple of years for its stock, Nike NYSE: NKE just gave investors a reason for renewed optimism. Following its fourth-quarter earnings report on June 26, the company's stock jumped close to 15% in a single session.
Shares of Nike (NKE), Wayfair (W), and other retailers with a significant production footprint in Vietnam rose Wednesday as President Trump said the U.S. reached a trade deal with the country.
Nike Inc (NYSE:NKE, ETR:NKE) shares moved higher after US President Donald Trump announced that the country has reached a trade deal with Vietnam. Vietnam is a key sourcing country for Nike's footwear production, which accounts for a significant portion of its supply chain.
A few popular socks, NIKE NKE and Target TGT have faced notable pressure over recent years, underperforming in a big way and regularly posting weaker-than-expected results.